p53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer

Hsu,Nan-Yung; Wu,Jeng-Yuan; Liu,Xiyong; Yen,Yun; Chen,Chih-Yi; Chou,Ming-Chih; Lee,Huei; Cheng,Ya-Wen

doi:10.3892/ol_00000108

July-August 2010 Volume 1 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-August 2010 Volume 1 Issue 4

Full Size Image

Article

p53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer

Authors:
- Nan-Yung Hsu
- Jeng-Yuan Wu
- Xiyong Liu
- Yun Yen
- Chih-Yi Chen
- Ming-Chih Chou
- Huei Lee
- Ya-Wen Cheng
View Affiliations / Copyright

Affiliations: Institute of Medicine, Chung Shan Medical University, 40203 Taiwan, R.O.C.
Pages: 609-613
|
Published online on: July 1, 2010

https://doi.org/10.3892/ol_00000108
Expand metrics +

Abstract

p53R2 is a small subunit of ribonucleotide reductase (RR) which has 80% homology to hRRM2 and metastasis-suppressing potential. Previous reports suggested that the expression of p53R2 is used as a prognostic factor and chemotherapy response indicator in several types of cancer. This study aimed to elucidate the association of p53R2 expression and the clinicopathological characteristics of early stage non-small cell lung cancer (NSCLC). Immunohistochemistry was conducted on a tissue array including 92 early stage NSCLC samples. Correlations between p53R2 and clinicopathological factors, recurrence/metastasis and outcomes were analyzed. The analyses showed that there was no correlation between p53R2 expression and the clinicopathological factors. Among disease-free patients during follow-up, patients with p53R2(+) had a better outcome than those with p53R2(−) (P=0.022). By using Cox multivariate regression analysis, p53R2 (risk factor 3.801; 95% CI 1.004-9.454; P=0.044) served as a prognostic biomarker in the prediction of the survival rate for NSCLC patients. Detection of the RR subunit p53R2 may therefore be a useful prognostic marker in early stage NSCLC.

View Figures

View References

1	Montain C: Revision in the International System for Staging Lung Cancer. Chest. 111:1710–1717. 1997. View Article : Google Scholar : PubMed/NCBI
2	WHO. The World Health Organization histological typing of lung tumors. Am J Clin Pathol. 77:123–136. 1982.
3	Reichard P: Ribonucleotide reductases: the evolution of allosteric regulation. Arch Biochem Biophys. 397:149–155. 2002. View Article : Google Scholar : PubMed/NCBI
4	Tanaka H, Arakawa H, Yamaguchi T, et al: A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 404:42–49. 2000. View Article : Google Scholar : PubMed/NCBI
5	Cerqueira N, Pereira S, Fernandes PA and Ramos MJ: Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy. Curr Med Chem. 12:1283–1294. 2005. View Article : Google Scholar : PubMed/NCBI
6	Shao J, Zhou B, Zhu L, et al: In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res. 64:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
7	Guittet O, Hakansson P, Voevodskaya N, et al: Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem. 276:40647–4051. 2001. View Article : Google Scholar
8	Piao C, Lin M, Kim HB, et al: Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2. Oncogene. 28:2173–2184. 2009. View Article : Google Scholar : PubMed/NCBI
9	Link PA, Baer MR, James SR, et al: p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res. 68:9358–9366. 2008. View Article : Google Scholar
10	Liu X, Zhou B, Xue L, et al: Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells. Clin Cancer Res. 12:6337–6344. 2006. View Article : Google Scholar : PubMed/NCBI
11	Furuta E, Okuda H, Aya K and Watabe K: Metabolic genes in cancer: the role in tumor progression and clinical implications. Biochim Biophys Acta. 1805:141–152. 2010.
12	Xu X, Page JL, Surtees JA, et al: Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms. Cancer Res. 68:2652–2660. 2008. View Article : Google Scholar : PubMed/NCBI
13	Uramoto H, Sugio K, Oyama T, et al: P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer. Anticancer Res. 25:983–988. 2006.PubMed/NCBI
14	Okumura H, Natsugoe S, Yokomalura N, et al: Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res. 12:3740–3744. 2006. View Article : Google Scholar : PubMed/NCBI
15	Yanamoto S, Kawasaki G, Yamada S, et al: Ribonucleotide reductase small subunit p53R2 promotes oral cancer invasion via the E-cadherin/beta-catenin pathway. Oral Oncol. 45:521–525. 2009. View Article : Google Scholar : PubMed/NCBI
16	Liu X, Zhou B, Xue L, et al: Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin Colorectal Cancer. 6:374–381. 2007. View Article : Google Scholar : PubMed/NCBI
17	Zhou BS, Tsai P, Ker R, et al: Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis. 16:43–49. 1998. View Article : Google Scholar : PubMed/NCBI
18	Fan H, Villegas C and Wright JA: Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci USA. 93:14036–14040. 1996. View Article : Google Scholar
19	Fan H, Huang A, Villegas C and Wright JA: The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci USA. 94:13181–13186. 1997. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

p53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles